Buffer system with stable pH value and application of buffer system in calcium acetate tablet in-vitro phosphorus binding test
By using the pH stable buffer system of boric acid-borax buffer and potassium dihydrogen phosphate-ditoxine phosphate buffer in the in vitro phosphorus binding test of calcium acetate tablets, the problem of pH instability in the existing technology was solved, and the The accurate phosphorus binding amount detection of calcium acetate tablets improves the accuracy of blood phosphorus control.
Patent Information
- Application Number
- CN202410965192.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
AI Technical Summary
In the existing in vitro phosphorus binding test of calcium acetate tablets, the pH value is unstable, which makes it impossible to accurately detect the phosphorus binding amount of calcium acetate tablets, which cannot effectively reflect the differences in preparation process and raw materials, affecting the accuracy of blood phosphorus control.
Using a pH-stable buffer system composed of boric acid-borax buffer and potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer, simulates the human intestinal environment, ensures that the test pH is 6.8, and passes calcium acetate tablets and these buffers. Reaction, determine the phosphorus binding amount.
The pH value stability of the in vitro phosphorus binding test of calcium acetate tablets was achieved, accurately reflecting the differences in the preparation process and raw materials of calcium acetate tablets, improving the accuracy of blood phosphorus control, and meeting the needs of bioequivalence research.
Smart Images

Figure CN118903439A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of calcium acetate tablets, and in particular to a buffer system with a stable pH value and its application in an in vitro phosphorus binding test of calcium acetate tablets. Background Art
[0002] Maintenance hemodialysis is currently an effective replacement therapy for chronic renal failure, but patients generally have poor control of blood phosphorus during hemodialysis treatment. Hyperphosphatemia may cause patients to have a variety of complications, such as secondary hyperparathyroidism, renal osteodystrophy and other serious complications, and hyperphosphatemia is also an important cause of death in patients with acute and chronic renal failure. Therefore, effective control of blood phosphorus levels in hemodialysis patients has important practical significance.
[0003] The main source of human blood phosphorus is food intake. Calcium acetate tablets are often used in the clinic to treat hyperphosphatemia caused by mid-to-late stage renal failure. Patients with hyperphosphatemia can reduce their blood phosphorus concentration by taking calcium acetate tablets with meals. Phosphorus in food combines with calcium acetate to form insoluble calcium phosphate, which is excreted from the body, thereby reducing the absorption of phosphorus by patients with hyperphosphatemia. The bioequivalence of calcium acetate tablets is usually evaluated by the calcium acetate tablet in vitro phosphorus binding test, that is, the phosphorus binding amount is used as an indicator to evaluate the release and effectiveness of calcium acetate tablets.
[0004] The publication number is CN109655418A, a calcium acetate tablet in vitro phosphorus binding test method discloses that calcium acetate tablets are subjected to phosphorus binding tests with at least 7 sodium phosphate buffers of different pH values, respectively, using sodium phosphate as phosphate, sodium phosphate dissociates into disodium hydrogen phosphate and sodium hydroxide in water, calcium acetate reacts with disodium hydrogen phosphate to generate calcium phosphate and acetic acid, acetic acid reacts with sodium hydroxide to produce sodium acetate and water, the pH value of the sodium phosphate buffer in the method is above 10, phosphorus binding reaction generates acetic acid, acetic acid and sodium hydroxide are acid-base neutralized, affected by chemical equilibrium, calcium ions and phosphates continuously generate calcium phosphate during the reaction, so the actual phosphorus binding amount of calcium acetate tablets cannot be accurately detected. In addition, phosphorus in food binds to calcium acetate in the small intestine, and the pH of the human intestinal tract is about 6.8. The strongly alkaline environment cannot sensitively and accurately reflect the differences in the preparation process and raw materials of calcium acetate tablets.
[0005] Therefore, it is necessary to provide a pH-stable buffer system that can accurately reflect the differences in the preparation process and raw materials of calcium acetate tablets. Summary of the invention
[0006] In order to solve or partially solve the problems existing in the related art, the present application provides an in vitro phosphorus binding test method for calcium acetate tablets with stable pH value, which can accurately reflect the differences in the preparation process and raw materials of calcium acetate tablets.
[0007] The present application provides a buffer system with stable pH value, wherein the buffer system consists of a buffer salt system and a phosphate system; the buffer salt system is a boric acid-borax buffer; the phosphate system is a potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer or a sodium dihydrogen phosphate-dipotassium hydrogen phosphate buffer.
[0008] Optionally, the phosphate system is a potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer.
[0009] Optionally, the concentrations of the buffer salt system and the phosphate system are both 0.15 mol / L, and the pH values are both 6.8.
[0010] The present application also provides the use of the above buffer system in an in vitro phosphorus binding test of calcium acetate tablets.
[0011] Optionally, include the following steps:
[0012] 1) Take boric acid-borax buffer into a reaction bottle and add calcium acetate tablets;
[0013] 2) After the calcium acetate tablets are completely dissolved, potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer is added to prepare a reaction solution;
[0014] 3) The reaction solution is placed on a constant temperature oscillator for oscillation, and filtered through a filter membrane to obtain a filtrate;
[0015] 4) Determine the content of free calcium and phosphorus in the filtrate and calculate the phosphorus binding capacity;
[0016] In step 1) and step 2), the concentrations of the boric acid-borax buffer and the potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer are both 0.15 mol / L, and the pH is both 6.8.
[0017] Optionally, in step 2), the amount of potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer added is 0-7.5 mmol.
[0018] Optionally, in step 3), the temperature of the constant temperature oscillator is 37° C., the oscillation frequency is 120 rpm, and the oscillation time is 90 min.
[0019] The technical solution provided by this application may have the following beneficial effects:
[0020] 1) In the present application, boric acid-borax buffer is used as a buffer salt system, and potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer or sodium dihydrogen phosphate-dipotassium hydrogen phosphate buffer is used as a phosphate system. The synergistic effect of the two can stabilize the pH value of the in vitro phosphate binding test of calcium acetate tablets.
[0021] 2) In this application, the pH of the phosphate system and the buffer salt system are both set to 6.8. The phosphate system and the buffer salt system are configured so that the pH of the reaction solution is close to 6.8, simulating the intestinal action environment of calcium acetate tablets, and can accurately reflect the differences in the preparation process and raw materials of calcium acetate tablets.
[0022] It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the present application. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The above and other objects, features and advantages of the present application will become more apparent through a more detailed description of exemplary embodiments of the present application in conjunction with the accompanying drawings, wherein the same reference numerals generally represent the same components in the exemplary embodiments of the present application.
[0024] Figure 1 It is a schematic diagram of phosphorus binding curves of calcium tablets of the same specification and different loading amounts made from the same raw material drug and the reference preparation shown in the present application;
[0025] Figure 2 It is a schematic diagram of the phosphorus binding capacity curve of calcium tablets of the same specifications made from different raw materials and reference preparations shown in this application. DETAILED DESCRIPTION
[0026] The embodiments of the present application will be described in more detail below with reference to the accompanying drawings. Although the embodiments of the present application are shown in the accompanying drawings, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided to make the present application more thorough and complete, and to fully convey the scope of the present application to those skilled in the art.
[0027] For the sake of clarity, the following examples are used to explain in detail. Unless otherwise specified, the materials used in the following examples are purchased from the market.
[0028] Example 1
[0029] A pH-stable buffer system, a phosphate system and a buffer salt system are added to a conical flask to prepare 150 ml of a reaction medium, and then calcium acetate tablets (specification of calcium acetate tablets is 0.667 mg) are added. The pH of the solution before and after the addition of the calcium acetate tablets is measured respectively;
[0030] The phosphate system was potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer with a concentration of 0.15 mol / L and a pH of 6.8;
[0031] The buffer salt system is boric acid-borax buffer with a concentration of 0.15 mol / L and a pH of 6.8.
[0032] Example 2
[0033] A pH-stable buffer system, a phosphate system and a buffer salt system are added to a conical flask to prepare a 150 ml reaction medium, and then calcium acetate tablets (the specification of calcium acetate tablets is 0.667 mg) are added. The pH of the solution before and after the addition of calcium acetate tablets is measured respectively;
[0034] The phosphate system was sodium dihydrogen phosphate-dipotassium hydrogen phosphate buffer with a concentration of 0.15 mol / L and a pH of 6.8;
[0035] The buffer salt system is boric acid-borax buffer with a concentration of 0.15 mol / L and a pH of 6.8.
[0036] Comparative Example 1
[0037] The difference between Comparative Example 1 and Example 1 is that the buffer salt system is a boric acid-potassium chloride buffer system.
[0038] Comparative Example 2
[0039] The difference between Comparative Example 2 and Example 1 is that the buffer salt system is a Tris-HCl buffer system.
[0040] Comparative Example 3
[0041] The difference between Comparative Example 3 and Example 1 is that the phosphate system is trisodium phosphate.
[0042] Comparative Example 4
[0043] The difference between Comparative Example 4 and Example 1 is that the phosphate system is disodium hydrogen phosphate.
[0044] Comparative Example 5
[0045] The difference between Comparative Example 5 and Example 1 is that the phosphate system is sodium dihydrogen phosphate.
[0046] Comparative Example 6
[0047] The difference between Comparative Example 6 and Example 1 is that the phosphate system is dipotassium hydrogen phosphate.
[0048] Comparative Example 7
[0049] The difference between Comparative Example 7 and Example 1 is that the phosphate system is potassium dihydrogen phosphate.
[0050] The pH change results after mixing different buffer salt systems and phosphate systems in Example 1, Example 2 and Comparative Examples 1 to Comparative Examples 7, as well as the change results after adding calcium acetate tablets are shown in Table 1.
[0051] Table 1 Effects of different buffer salt systems and phosphate systems on pH stability
[0052]
[0053]
[0054] As shown in Table 1, the pH of the buffer salt system and the phosphate system after mixing is quite different from the human intestinal pH of 6.8 when the boric acid-borax buffer and the potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer are used as the buffer salt system and the Tris-HCl buffer system, and the pH of the phosphate system after mixing is quite different from the human intestinal pH of 6.8; the pH of the boric acid-borax buffer and the potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer (pH before adding calcium acetate tablets) is 6.79, and the pH of the boric acid-borax buffer and the sodium dihydrogen phosphate-dipotassium hydrogen phosphate buffer (pH before adding calcium acetate tablets) is 6.84, which are close to the intestinal environment of calcium acetate tablets. However, since sodium dihydrogen phosphate is difficult to dissolve, the phosphate system in the subsequent calcium acetate tablet in vitro phosphorus binding test uses potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer. And the use of potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer can reduce the ion interference caused by ICP-OES determination.
[0055] Example 3
[0056] A calcium acetate tablet in vitro phosphorus binding test method comprises the following steps:
[0057] 1) Accurately pipette 150ml, 149.0ml, 148.0ml, 146.0ml, 144.0ml, 140.0ml, 135.0ml and 130.0ml of 0.15mol / L pH6.8 boric acid-borax buffer into conical flasks respectively, and add calcium acetate tablets (specification G of calcium acetate tablets is 0.667mg);
[0058] 2) After the calcium acetate tablets are completely dissolved, accurately measure 0.0 ml, 1.0 ml, 2.0 ml, 4.0 ml, 6.0 ml, 10.0 ml, 15.0 ml and 20.0 ml of 0.5 mol / L pH 6.8 potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer (the amount of potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer added is 0.0 mmol, 0.5 mmol, 1.0 mmol, 2.0 mmol, 3.0 mmol, 5.0 mmol, 7.5 mmol and 10.0 mmol, respectively) to prepare 150 ml of reaction solution;
[0059] 3) The reaction solution was placed on a constant temperature oscillator for oscillation, and filtered through a filter membrane to obtain a filtrate; the temperature of the constant temperature oscillator was 37° C., the oscillation frequency was 120 rpm, and the oscillation time was 90 min; the pore size of the filter membrane was 0.45 μm;
[0060] 4) Determine the content of free calcium and phosphorus in the filtrate and calculate the phosphorus binding amount.
[0061] The free calcium and free phosphorus in the reaction solution were detected by inductively coupled plasma emission spectrometry according to the 2020 edition of ChP Part IV 0411. The emission spectrum detection parameters are shown in Table 2. After the detection, the calcium binding rate and phosphate binding amount were calculated, and the calculation results are shown in Table 3.
[0062] Table 2 Emission spectrum detection parameters
[0063] Nebulizer gas flow rate 0.8L / min Auxiliary gas flow rate 0.2L / min Plasma gas flow rate 15L / min Analytical power 1.3kw Observation method Axial observation Points Peak area Pre-burning time 35s Injection rate 1.5mL / min Wavelength / nm(Ca) 317.933 Wavelength / nm(P) 213.617
[0064] Table 3 Calculation results of calcium binding rate and phosphate binding amount
[0065]
[0066] As shown in Table 3, as the phosphate concentration increases, the calcium binding rate increases. When the amount of phosphate added is greater than 7.5 mmol, the calcium ions are completely precipitated, and when a large amount of free phosphate exists, it interferes with the flame atomic absorption spectrometry determination of free calcium ions. Finally, the in vitro phosphorus-binding phosphate addition amount of 0-7.5 mmol (0.15 mol / L potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer is added to 15.0 ml) is selected to meet the technical requirements and reduce the interference of phosphate on the determination of calcium ions.
[0067] The test method of the present application is used to test the bioequivalence of calcium tablets of the same specification but different filling amounts made from the same raw material drug and calcium tablets of the same specification made from different raw materials drug.
[0068] The same raw materials purchased from the same manufacturer were used to make calcium tablets with the same specifications but different dosages for bioequivalence testing:
[0069] 1) Accurately pipette 150ml, 149.0ml, 148.0ml, 146.0ml, 144.0ml, 140.0ml and 135.0ml of 0.15mol / L pH6.8 boric acid-borax buffer into conical flasks respectively, and add the same API to prepare calcium tablets of the same specification but different loading amounts (the specification of calcium acetate tablets is 0.667mg);
[0070] 2) After the calcium acetate tablets are completely dissolved, accurately measure 0.0 ml, 1.0 ml, 2.0 ml, 4.0 ml, 6.0 ml, 10.0 ml and 15.0 ml of 0.5 mol / L pH 6.8 potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer (the amount of potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer added is 0.0 mmol, 0.5 mmol, 1.0 mmol, 2.0 mmol, 3.0 mmol, 5.0 mmol and 7.5 mmol, respectively) to prepare 150 ml of reaction solution;
[0071] 3) The reaction solution was placed on a constant temperature oscillator for oscillation, and filtered through a filter membrane to obtain a filtrate; the temperature of the constant temperature oscillator was 37° C., the oscillation frequency was 120 rpm, and the oscillation time was 90 min; the pore size of the filter membrane was 0.45 μm;
[0072] 4) Determine the content of free calcium and phosphorus in the filtrate and calculate the phosphorus binding amount.
[0073] Table 4 Phosphorus binding capacity of calcium tablets of the same specification and different loadings made with the same raw material
[0074]
[0075] The similarity factors f2 of the average phosphorus binding and average free calcium ions of the homemade samples (prescription 1 calcium tablets, prescription 2 calcium tablets and prescription 3 calcium tablets) and the reference preparation were calculated according to the following formula. The results are shown in Table 4. The similarity factors f2 of phosphorus binding of three batches of homemade calcium acetate tablets of different specifications made with the same raw material were 63.33, 62.53 and 66.14, respectively, indicating that the phosphorus binding curves of the homemade samples and the reference preparation were similar. The phosphorus binding curves of the homemade samples and the reference preparation are shown in the figure Figure 1 shown.
[0076] f2=50·log{[1+(1 / n)Σ t=1 n (R t -T t ) 2 ] -0.5 ·100}n is the number of phosphate concentrations;
[0077] Rt is the phosphate binding amount when the phosphate concentration of the reference sample is t (or the amount of free calcium ions when the phosphate concentration of the reference sample is t);
[0078] Tt is the phosphate binding amount when the phosphate concentration of the homemade sample is t (or the amount of free calcium ions when the phosphate concentration of the homemade sample is t);
[0079] As shown in Table 4, when the amount of phosphate added was 7.5 mmol, the phosphate binding amount was the largest. The maximum phosphorus binding amounts of the reference preparation (R) and the homemade sample (T) were 109.86 mg, 115.09 mg, 115.04 mg, and 115.47 mg, respectively. The phosphorus binding ratios T / R were 104.76%, 104.71%, and 105.11%, respectively, which met the limit requirements of the "Technical Guidelines for Bioequivalence Studies of Calcium Acetate Tablets", indicating that the homemade and reference preparations were bioequivalent.
[0080] Calcium tablets of the same specifications were prepared from different APIs purchased from different manufacturers for bioequivalence testing:
[0081] 1) Accurately pipette 150ml, 149.0ml, 148.0ml, 146.0ml, 144.0ml, 140.0ml and 135.0ml of 0.15mol / L pH6.8 boric acid-borax buffer into conical flasks respectively, and add calcium tablets of the same specification (calcium acetate tablets are all 0.667mg) made from raw materials of different manufacturers;
[0082] 2) After the calcium acetate tablets are completely dissolved, accurately measure 0.0 ml, 1.0 ml, 2.0 ml, 4.0 ml, 6.0 ml, 10.0 ml and 15.0 ml of 0.5 mol / L pH 6.8 potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer (the amount of potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer added is 0.0 mmol, 0.5 mmol, 1.0 mmol, 2.0 mmol, 3.0 mmol, 5.0 mmol and 7.5 mmol, respectively) to prepare 150 ml of reaction solution;
[0083] 3) The reaction solution was placed on a constant temperature oscillator for oscillation, and filtered through a filter membrane to obtain a filtrate; the temperature of the constant temperature oscillator was 37° C., the oscillation frequency was 120 rpm, and the oscillation time was 90 min; the pore size of the filter membrane was 0.45 μm;
[0084] 4) Determine the content of free calcium and phosphorus in the filtrate and calculate the phosphorus binding amount.
[0085] Table 5 Phosphorus binding capacity of calcium tablets of the same specifications prepared using different raw materials
[0086]
[0087]
[0088] The similarity factor f2 of the average phosphorus binding and average free calcium ion of the homemade samples (raw material 1 calcium tablets, raw material 2 calcium tablets and raw material 3 calcium tablets) and the reference preparation was calculated according to the following formula. The results are shown in Table 5. The similarity factors f2 of the phosphorus binding of the three batches of homemade calcium acetate tablets using different raw materials were 49.89, 66.91 and 62.56, respectively, indicating that the first group of raw materials did not meet the quality standards, and the phosphorus binding curves of the homemade preparation and the reference preparation were not similar. The phosphorus binding curves of the homemade preparations and the reference preparations of the other two groups of raw materials were similar. The phosphorus binding curves of the homemade samples and the reference preparations are shown in Figure 5. Figure 2 shown.
[0089] f2=50·log{[1+(1 / n)Σ t=1 n (R t -T t ) 2 ] -0.5 ·100}
[0090] n is the number of phosphate concentrations;
[0091] Rt is the phosphate binding amount when the phosphate concentration of the reference sample is t (or the amount of free calcium ions when the phosphate concentration of the reference sample is t);
[0092] Tt is the phosphate binding amount when the phosphate concentration of the homemade sample is t (or the amount of free calcium ions when the phosphate concentration of the homemade sample is t);
[0093] As shown in Table 5, when the amount of phosphate added was 7.5 mmol, the phosphate binding amount was the largest. The maximum phosphorus binding amounts of the reference preparation (R) and the homemade sample (T) were 109.86 mg, 92.41 mg, 109.82 mg, and 116.94 mg, respectively. The phosphorus binding ratios T / R were 84.12%, 99.96%, and 106.44%, respectively. Group 1 did not meet the limit requirements of the "Technical Guidelines for Bioequivalence Studies of Calcium Acetate Tablets", indicating that the homemade group could not achieve bioequivalence with the reference, while the other two groups were bioequivalent.
[0094] From Tables 4 and 5, it can be seen that this detection method can clearly distinguish the phosphorus binding amount of calcium acetate tablets made from different raw materials, and then distinguish the product quality.
[0095] Based on the ecological environment of the human intestine, this application uses boric acid-borax buffer as the buffer salt system and potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer as the phosphate system. Buffer salt systems and phosphate systems with strong buffering capacity and similar pH environment to the human intestinal tract are selected, which can effectively examine the biological equivalence of calcium acetate tablets and avoid the pH change of the reaction system due to different phosphate selections. The system fails to truly reflect the bioavailability of calcium acetate tablets.
[0096] The embodiments of the present application have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and changes will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or improvements to the technology in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.
Claims
1. A pH-stable buffer system, characterized in that: The buffer system consists of a buffer salt system and a phosphate system; the buffer salt system is a boric acid-borax buffer; the phosphate system is a potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer or a sodium dihydrogen phosphate-dipotassium hydrogen phosphate buffer.
2. The buffer system according to claim 1, characterized in that The phosphate system is potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer.
3. The buffer system according to claim 1, characterized in that The concentrations of the buffer salt system and the phosphate system are both 0.15 mol / L, and the pH is both 6.
8.
4. Use of the buffer system according to any one of claims 1 to 3 in an in vitro phosphate binding test of calcium acetate tablets.
5. The use according to claim 4, characterized in that: The following steps are involved: 1) Take boric acid-borax buffer into a reaction bottle and add calcium acetate tablets; 2) After the calcium acetate tablets are completely dissolved, potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer is added to prepare a reaction solution; 3) The reaction solution is placed on a constant temperature oscillator for oscillation, and filtered through a filter membrane to obtain a filtrate; 4) Determine the content of free calcium and phosphorus in the filtrate and calculate the phosphorus binding capacity; In the step 1) and the step 2), the concentrations of the boric acid-borax buffer and the potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer are both 0.15 mol / L, and the pH is both 6.
8.
6. The use according to claim 5, characterized in that: The amount of potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer added in step 2) is 0-7.5 mmol.
7. The use according to claim 5, characterized in that: In the step 3), the temperature of the constant temperature oscillator is 37° C., the oscillation frequency is 120 rpm, and the oscillation time is 90 min.
